Literature DB >> 22893038

Vasodilator isoxsuprine alleviates symptoms of oral submucous fibrosis.

Chetan J Bhadage1, Hemant R Umarji, Karan Shah, Hannamari Välimaa.   

Abstract

OBJECTIVES: The aim of the study was to compare the effectiveness of vasodilator isoxsuprine to dexamethasone with hyaluronidase injections and physiotherapy in the treatment of oral submucous fibrosis.
MATERIALS AND METHODS: Forty patients with oral submucous fibrosis were randomly assigned into three groups. Group A patients (n = 15) received 10 mg isoxsuprine tablets four times per day, group B (n = 15) biweekly dexamethasone with hyaluronidase intralesional injections, and group C (n = 10) placebo tablets. In addition, all patients were instructed physiotherapy exercises. The treatment time was 6 weeks and patients were followed-up for 4 months thereafter. The effect of the treatment was evaluated by measurements of inter-incisal distance and oral burning sensation and evaluation of histological findings of the diseased mucosa.
RESULTS: Mouth opening increased and burning sensation decreased significantly in all groups, but the effects were significantly greater in groups receiving either oral isoxsuprine or dexamethasone with hyaluronidase injections in addition to physiotherapy. The decrease in burning sensation occurred more rapidly in patients receiving intralesional dexamethasone with hyaluronidase. Histological improvement was not observed in any of the groups.
CONCLUSIONS: Oral isoxsuprine as well as dexamethasone with hyaluronidase injections combined to physiotherapy alleviate symptoms of oral submucous fibrosis significantly more efficiently than physiotherapy alone. CLINICAL RELEVANCE: Oral isoxsuprine can be considered as a new candidate drug for the treatment of oral submucous fibrosis. Physiotherapy exercises provide relief of symptoms and should be instructed to all patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22893038     DOI: 10.1007/s00784-012-0824-z

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  24 in total

Review 1.  Proposed clinical classification for oral submucous fibrosis.

Authors:  Chandramani B More; Sunanda Das; Hetul Patel; Chhaya Adalja; Vaishnavee Kamatchi; Rashmi Venkatesh
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

2.  Management of oral submucous fibrosis: a conservative approach.

Authors:  R M Borle; S R Borle
Journal:  J Oral Maxillofac Surg       Date:  1991-08       Impact factor: 1.895

3.  Oral submucous fibrosis: a new concept in surgical management. Report of 100 cases.

Authors:  J N Khanna; N N Andrade
Journal:  Int J Oral Maxillofac Surg       Date:  1995-12       Impact factor: 2.789

Review 4.  A systematic review of medical interventions for oral submucous fibrosis and future research opportunities.

Authors:  A R Kerr; S Warnakulasuriya; A J Mighell; T Dietrich; M Nasser; J Rimal; A Jalil; M M Bornstein; T Nagao; F Fortune; V H Hazarey; P A Reichart; S Silverman; N W Johnson
Journal:  Oral Dis       Date:  2011-04       Impact factor: 3.511

5.  Oral submucous fibrosis--a new treatment regimen.

Authors:  D Gupta; S C Sharma
Journal:  J Oral Maxillofac Surg       Date:  1988-10       Impact factor: 1.895

6.  Oral submucous fibrosis.

Authors:  J J Pindborg; S M Sirsat
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1966-12

Review 7.  Cerebral vasodilators (second of two parts).

Authors:  P Cook; I James
Journal:  N Engl J Med       Date:  1981-12-24       Impact factor: 91.245

8.  Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis.

Authors:  Karwan A Moutasim; Veronika Jenei; Karen Sapienza; Daniel Marsh; Paul H Weinreb; Shelia M Violette; Mark P Lewis; John F Marshall; Farida Fortune; Waninayaka M Tilakaratne; Ian R Hart; Gareth J Thomas
Journal:  J Pathol       Date:  2010-10-25       Impact factor: 7.996

9.  Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis.

Authors:  Mangal Singh; H S Niranjan; Ravi Mehrotra; Devashish Sharma; S C Gupta
Journal:  Indian J Med Res       Date:  2010-05       Impact factor: 2.375

10.  Efficacy of lycopene in the management of oral submucous fibrosis.

Authors:  Abhinav Kumar; Anjana Bagewadi; Vaishali Keluskar; Mohitpal Singh
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-10-24
View more
  6 in total

Review 1.  Precancerous lesions of oral mucosa.

Authors:  Gurkan Yardimci; Zekayi Kutlubay; Burhan Engin; Yalcin Tuzun
Journal:  World J Clin Cases       Date:  2014-12-16       Impact factor: 1.337

2.  Medicinal management of oral submucous fibrosis in the past decade- A systematic review.

Authors:  Chandramani B More; Deepa Jatti Patil; Naman R Rao
Journal:  J Oral Biol Craniofac Res       Date:  2020-08-19

Review 3.  Oral submucous fibrosis: a contemporary narrative review with a proposed inter-professional approach for an early diagnosis and clinical management.

Authors:  Naman R Rao; Alessandro Villa; Chandramani B More; Ruwan D Jayasinghe; Alexander Ross Kerr; Newell W Johnson
Journal:  J Otolaryngol Head Neck Surg       Date:  2020-01-08

Review 4.  Comparative Efficacy of Interventions for the Management of Oral Submucous Fibrosis: A Systematic Review and Network Meta-Analysis.

Authors:  Divya Gopinath; Lai Mong Hui; Sajesh K Veettil; Athira Balakrishnan Nair; Mari Kannan Maharajan
Journal:  J Pers Med       Date:  2022-08-01

Review 5.  Oral submucous fibrosis: an update.

Authors:  Uwe Wollina; Shyam B Verma; Fareedi Mukram Ali; Kishor Patil
Journal:  Clin Cosmet Investig Dermatol       Date:  2015-04-13

6.  VEGF gene transfection restores the angiogenesis of oral submucous fibrosis in mice.

Authors:  Ying Sun; Tao Wang; Qi-Tao Wen; Da-Hai Yu; Jing-Xin Chen
Journal:  Ann Transl Med       Date:  2021-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.